Bonus Biogroup Total Assets
Bonus Biogroup total assets. Based on the latest financial reports, Bonus Biogroup (BONS) holds total assets worth ILA15.44 Million ILA (≈ $41.40K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BONS stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Bonus Biogroup (2008–2025)
Total assets of Bonus Biogroup from 2008 to 2025. This chart illustrates how Bonus Biogroup's total assets have evolved over time, based on quarterly financial data. See Bonus Biogroup stock price for real-time trading data and today's change.
Bonus Biogroup - Asset Composition Analysis
Bonus Biogroup Total Assets Breakdown (December 2025)
Bonus Biogroup total assets breakdown as of December 2025. Bonus Biogroup's total assets of ILA15.44 Million consist of 11.4% current assets and 88.7% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 1.5% |
| Accounts Receivable | ILA624.00K | 4.0% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Bonus Biogroup's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BONS net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bonus Biogroup's current assets represent 11.4% of total assets in 2025, a decrease from 25.2% in 2008.
- Cash Position: Cash and equivalents constituted 1.5% of total assets in 2025, up from 0.1% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 4.0% of total assets.
Bonus Biogroup Competitors by Total Assets
Key competitors of Bonus Biogroup based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Bonus Biogroup - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.13 | 0.91 | 1.02 |
| Quick Ratio | 0.13 | 0.91 | 1.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA-12.24 Million | ILA-726.00K | ILA363.00K |
Bonus Biogroup - Advanced Valuation Insights
This section examines the relationship between Bonus Biogroup's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 41.30 |
| Latest Market Cap to Assets Ratio | 3.33 |
| Asset Growth Rate (YoY) | -34.0% |
| Total Assets | ILA15.44 Million |
| Market Capitalization | $51.35 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Bonus Biogroup's assets at a significant premium (3.33x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Bonus Biogroup's assets decreased by 34.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bonus Biogroup (2008–2025)
The table below shows the annual total assets of Bonus Biogroup from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ILA15.44 Million ≈ $41.40K |
-34.03% |
| 2024-12-31 | ILA23.41 Million ≈ $62.75K |
-47.86% |
| 2023-12-31 | ILA44.89 Million ≈ $120.35K |
-39.84% |
| 2022-12-31 | ILA74.61 Million ≈ $200.03K |
-28.48% |
| 2021-12-31 | ILA104.32 Million ≈ $279.68K |
+102.82% |
| 2020-12-31 | ILA51.44 Million ≈ $137.90K |
+635.87% |
| 2019-12-31 | ILA6.99 Million ≈ $18.74K |
-31.19% |
| 2018-12-31 | ILA10.16 Million ≈ $27.23K |
+82.14% |
| 2017-12-31 | ILA5.58 Million ≈ $14.95K |
+92.58% |
| 2016-12-31 | ILA2.90 Million ≈ $7.76K |
-49.69% |
| 2015-12-31 | ILA5.76 Million ≈ $15.43K |
+27.26% |
| 2014-12-31 | ILA4.52 Million ≈ $12.13K |
-44.55% |
| 2013-12-31 | ILA8.16 Million ≈ $21.87K |
-7.86% |
| 2012-12-31 | ILA8.85 Million ≈ $23.73K |
+88430.00% |
| 2011-12-31 | ILA10.00K ≈ $26.81 |
-99.84% |
| 2010-12-31 | ILA6.07 Million ≈ $16.28K |
-87.70% |
| 2009-12-31 | ILA49.39 Million ≈ $132.40K |
-2.79% |
| 2008-12-31 | ILA50.81 Million ≈ $136.21K |
-- |
About Bonus Biogroup
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of… Read more